Overview
Lysosomal disease with hypertrophic cardiomyopathy (Orphanet code 217581) is a clinical grouping rather than a single disease entity. It encompasses a set of lysosomal storage disorders that share the prominent feature of hypertrophic cardiomyopathy — a condition in which the heart muscle becomes abnormally thickened, making it harder for the heart to pump blood effectively. Lysosomal storage disorders in this category result from deficiencies in specific lysosomal enzymes or proteins, leading to the accumulation of substrates within cells, particularly affecting cardiac tissue. Notable diseases that fall under this umbrella include Fabry disease, Pompe disease (glycogen storage disease type II), Danon disease, and certain mucopolysaccharidoses, each of which can present with significant cardiac hypertrophy. The body systems affected vary depending on the specific underlying lysosomal disorder but commonly include the cardiovascular system (hypertrophic cardiomyopathy, arrhythmias, heart failure), the musculoskeletal system (myopathy, exercise intolerance), and the nervous system (neuropathy or cognitive involvement in some forms). Additional features may include hepatosplenomegaly, skeletal abnormalities, and respiratory compromise. The severity and age of onset depend on the specific enzyme deficiency and residual enzyme activity. Treatment approaches differ based on the specific lysosomal disease identified. Enzyme replacement therapy (ERT) is available for some conditions, such as Fabry disease and Pompe disease, and can help slow disease progression. Other therapeutic strategies include substrate reduction therapy, pharmacological chaperone therapy, and supportive cardiac management including medications for heart failure and arrhythmias. Genetic counseling is recommended for affected families. Early diagnosis through genetic testing and cardiac imaging is important for optimizing outcomes.
Variable
Can be inherited in different ways depending on the underlying gene
Variable
Can begin at different ages, from infancy through adulthood
Treatments
No FDA-approved treatments are currently listed for Lysosomal disease with hypertrophic cardiomyopathy.
View clinical trials →Clinical Trials
View all trials with filters →No actively recruiting trials found for Lysosomal disease with hypertrophic cardiomyopathy at this time.
New trials open frequently. Follow this disease to get notified.
Rare Disease Specialist
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Travel Grants
No travel grants are currently matched to Lysosomal disease with hypertrophic cardiomyopathy.
Community
No community posts yet. Be the first to share your experience with Lysosomal disease with hypertrophic cardiomyopathy.
Start the conversation →Latest news about Lysosomal disease with hypertrophic cardiomyopathy
No recent news articles for Lysosomal disease with hypertrophic cardiomyopathy.
Follow this condition to be notified when news becomes available.
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Common questions about Lysosomal disease with hypertrophic cardiomyopathy
What is Lysosomal disease with hypertrophic cardiomyopathy?
Lysosomal disease with hypertrophic cardiomyopathy (Orphanet code 217581) is a clinical grouping rather than a single disease entity. It encompasses a set of lysosomal storage disorders that share the prominent feature of hypertrophic cardiomyopathy — a condition in which the heart muscle becomes abnormally thickened, making it harder for the heart to pump blood effectively. Lysosomal storage disorders in this category result from deficiencies in specific lysosomal enzymes or proteins, leading to the accumulation of substrates within cells, particularly affecting cardiac tissue. Notable diseas
Which specialists treat Lysosomal disease with hypertrophic cardiomyopathy?
5 specialists and care centers treating Lysosomal disease with hypertrophic cardiomyopathy are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.